Want to see HK:2575 full AI Analyst Report?
2575 Stock Chart & Stats
HK$12.95
--
Market closed
HK$12.95
--
Day’s Range― - ―
52-Week RangeHK$8.01 - HK$96.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.20M
Market Cap
HK$4.30B
Enterprise ValueHK$6.24K
Total Cash (Recent Filing)HK$216.62M
Total Debt (Recent Filing)HK$1.37M
Price to Earnings (P/E)―
Beta2.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding517,947,800
10 Day Avg. Volume2,752,707
30 Day Avg. Volume1,199,537
Financial Highlights & Ratios
PEG Ratio2.47
Price to Book (P/B)23.93
Price to Sales (P/S)650.34
P/FCF Ratio-163.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue ScalingSharp revenue expansion across two consecutive years indicates meaningful commercial progress and growing business activity. If this trajectory continues, greater scale can broaden market presence, improve operating leverage, and provide a stronger foundation for future profitability.
Low Financial LeverageVery low debt relative to equity reduces financial risk and preserves flexibility for continued investment. Rising equity and assets also provide a stronger capitalization base, allowing the company more capacity to support development and commercial expansion without heavy leverage.
Improving Gross MarginThe shift to a positive gross margin is an important sign that the underlying commercial model is improving as revenue scales. Continued margin gains could strengthen unit economics and move the company closer to sustainable profitability, even though operating costs remain high.
Bears Say
Persistent LossesContinued operating and net losses show that the company has not yet achieved sustainable profitability despite rapid revenue growth. Persistent losses can constrain internal reinvestment, increase dependence on external funding, and make execution of the growth strategy more financially demanding.
Negative Cash GenerationNegative operating and free cash flow indicate that the business is not yet self-funding and continues to consume cash while pursuing growth. Although free cash flow improved in 2025, ongoing cash burn can limit strategic flexibility and leave execution dependent on continued funding.
Weak Returns On CapitalConsistently negative return on equity means the enlarged capital base is not yet producing value for shareholders. This reflects weak earnings conversion and raises the importance of improving operating efficiency, margins, and profitability before additional capital can generate attractive returns.
Xuanzhu Biopharmaceutical Co., Ltd. Class H News
2575 FAQ
What was Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Xuanzhu Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$8.01 and its highest was HK$96.90 in the past 12 months.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap is HK$4.30B.
When is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xuanzhu Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Xuanzhu Biopharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Xuanzhu Biopharmaceutical Co., Ltd. Class H pay dividends?
Xuanzhu Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xuanzhu Biopharmaceutical Co., Ltd. Class H have?
Xuanzhu Biopharmaceutical Co., Ltd. Class H has 517,947,800 shares outstanding.
What happened to Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xuanzhu Biopharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xuanzhu Biopharmaceutical Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
53.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xuanzhu Biopharmaceutical Co., Ltd. Class H
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―